The World Health Organization (WHO) estimates that over 2.5 million people globally suffer from Multiple Sclerosis (MS). With the present global population growing to an unprecedented height of 6.5 billion in 2005 and growth rate anticipated to reach 7.6 billion by 2020, the prevalence and onset of MS in children and particularly adults is expected to rise exponentially.

According to the National Multiple Sclerosis Society, an approximated 400,000 Americans have MS. In Europe over 500,000 are projected to have MS with large economic implications to healthcare providers. The clinical presentation of sufferers of the various forms of MS, over the past decade, have been treated with the following FDA approved disease modifying drugs (DMDs)-

Avonex (interferon beta-1a; Biogen Idec)
Betaseron (interferon beta-1b; Berlex, Inc./Schering)
Copaxone (glatiramer acetate; Teva and Sanofi- Aventis)
Novantrone (mitoxantrone; Serono International)
Rebif (interferon beta-1a; Serono/Pfizer) and
Tysabri (natalizumab; Biogen Idec and Elan Corp) re-entry into the market in July 2006

In 2006, the disease modifying drugs generated total global revenues of $5.4 billion, with a larger percentage of this revenue accounted for in the seven major markets (7MMs)- US, Japan, France, Germany, Italy, UK, and Spain. Visiongain believes that, as the larger Biopharmaceutical companies behind these products continue to advance on the product lifecycle of these disease modifying drugs, MS pharmaceutical treatments in these major markets are set to experience increased revenues. To find out exactly how big these increases will be, you should order this report today.

The disease modifying drugs on the MS market although effective are administered intravenously, intramuscularly or subcutaneously with much discomfort to MS patients. This has prompted a new wave of R&D heralded by top biopharmaceutical companies- Biogen Idec (BG-12), BioMS (MBP8298), Genzyme (Alemtuzumab), Merck Serono (Mylinax) ,Novartis (FTY720) ,Pipex (Trimesta), Sanofi-Aventis (Teriflunomide) and Teva (Laquinomide) into delivering oral MS therapeutics presently in late phase clinical studies to the markedly underserved MS market.

Visiongain believes the entry of a first oral MS product into the market will oscillate the markets' dynamics, which have been long dominated by injectable products, and in doing so will acquire a significant market share. Furthermore the successful product will set a benchmark for host of other compounds to penetrate the oral therapeutics sector worth over $26 billion globally.

Visiongain' s Multiple Sclerosis Market Analysis & Forecasts Report, 2007-2022, delivers information on a vast array of compounds, in various phases of clinical trials, being investigated to improve on the clinical efficacy of present therapies and also bring relief to patients experiencing relapsing-remitting MS (RRMS), Primary progressive MS (PPMS), Secondary progressive MS (SPMS) often followed by (RRMS). This report presents strategies employed by top companies to increase their year-on-year fiscal consolidation of revenues through the delivery of more than one product into the market. The report also presents an in-depth analysis on why the UK MS market is lagging behind its EU counterparts in terms of MS disease modifying drugs annual turn-over, despite being one of the strongest markets in the EU.

With country-by-country focus on the markets of:

US
UK
Germany
Japan
France
Italy
Spain

This report includes detailed five-year forecasts over the period 2007-2012, and NOW features 10 and 15 year forecasts to help you understand the medium-term prospects for these markets.

Why You Must Buy This Report:

This report features tables, graphs and charts, news, insights, the past and present developments in Market. This report will provide you with the complete understanding of the market indications for MS, the competition between companies into bringing the first oral MS product to revolutionized MS treatment, coupled with the domination of market share. When you buy this report, you will also get an understanding, through our overview, of how present changes in Governmental Pharmaceutical Policies will impact on the market strength of MS products in the 7MM. The Multiple Sclerosis Market Analysis & Forecasts 2007-2022 report is a must buy, because it presents in-depth and unbiased financial analysis for the near-term, medium-term and the long-term, market dynamics. When you buy the Visiongain 2007 MS report, you will be buying current and vital information on the growing prevalence of Paediatric MS and the value it adds to the global MS market.

Key questions that this report answers are:

How companies intend to sustain long term year-on-year MS revenues growth?
What strategic advancement on product lifecycle will boost revenues in the long- term?
What influence US Medicare Part D will have on the potential growth of US DMDs market?
Which companies are at the forefront of oral MS R&D?
Which oral compounds are in late phase studies?
Which company' s oral product is imminent to reach the market?
What decisions influenced UK NICE approval of Tysabri?
Why Tysabri will rejuvenate the UK MS market?
Will the DMDs in the 10-year (2002-2012) UK NICE "Risk Sharing Scheme" be cost-effective after 2012?
What is Paediatic MS and which treatments are preferred?

Unique benefits to you when you order this report:

Executive Summary

Chart E1 Demographics of MS across Seven Major Markets
Chart E2 Avonex Revenues ($m) across seven major markets, 2006
Chart E3 Copaxone Revenues ($m) across six major markets, 2006
Chart E4 Rebif Revenues ($m) across six major markets, 2006
Chart E5 Betaseron/Betaferon Revenues ($m) across seven major markets, 2006
Chart E6 Novantrone Revenues ($m) across seven major markets, 2006
Chart E7 Tysabri Revenues ($m) in US and Germany, 2006
Table E1 MS Revenue Forecast for Seven Major Markets, 2007-2012
Chart E8 MS Revenue Forecast for Seven Major Markets, 2007-2012
Table E2MS Revenue Forecast for Other Markets 2007-2012
Chart E9 MS Revenue Forecast for Other Markets 2007-2012

Chapter 1. Introduction to Multiple Sclerosis (MS)

1.1Introduction

Chapter 2. Defining Multiple Sclerosis

2.1.1 Benign MS
2.1.2 Relapse-remitting MS
2.1.3 Primary progressive MS
2.1.4 Secondary progressive
2.1.5 Progressive relapsing MS
2.2 Symptoms and Differential Diagnosis
- 2.2.1 Primary symptoms
- 2.2.2 Secondary symptoms
- 2.2.3 Tertiary symptoms
- 2.2.4 Diagnosis of MS
2.3 The Risk factors of MS
- 2.3.1 Immunologic Factors
- 2.3.2 Environmental Effects may influence MS Incidence
- 2.3.3 The Viral Induction of MS is possible
- 2.3.4 The Genetic Basis of MS Exists
- 2.3.5 Hormones Predispose Women to MS
2.4 The Demographics of MS
Chart 2.1 Demographics of MS across Seven Major Markets

Chapter 3. Pharmaceutical Products for MS Treatment

3.1Current Pharmaceutical Drug Therapies
Table 3.1. The Major Drug Treatments of MS
3.2 Relapsing-Remitting MS
- 3.2.1 Avonex (Interferon beta 1a) to Reduce Severity of MS
- 3.2.2 Rebif (Interferon beta 1a)
- 3.2.3 Betaseron (Interferon beta 1b)
- 3.2.4 Copaxone (Glatiramer acetate)
3.4 Antineoplastic Drugs (Relapse-Remitting & Secondary progressive)
- 3.4.1 Cancer Drug, Novantrone (Mixonatrone) Benefits MS Sufferers
- 3.4.2 Taxanes
  - 3.4.2.1 Taxol (paclitaxel)
- 3.4.3 Immunosuppressants - Secondary Progressive and Worsening Relapse-Remitting MS
  - 3.4.3.1 Imuran (Azathioprine)
  - 3.4.3.2 Sandimmune (Cyclosporine)
3.5 Corticosteroids

Chapter 4. Leading Companies behind MS Therapy

4.1 Key Companies delivering MS Therapy
- 4.1.1 Biogen Idec and Elan Pharmeceuticals
- 4.1.2Merck Serono
- 4.1.3 Bayer-Schering Pharmaceuticals' Betaseron
- 4.1.4 Teva and Sanofi Aventis

Chapter 5. Oral MS Pharmaceuticals Research and Development (R&D)

5.1 Oral Market Industry
Table 5.1. Factors influencing oral delivery of pharmaceutical products
- 5.1.1 Oral drugs development for MS
- 5.1.2 Leading companies in Oral delivery of MS therapeutics
  - 5.1.2.1 Biogen Idec and UCB
  - 5.1.2.2 Teva' s Laquinomod
  - 5.1.2.3 Serono' s Mylinax oral formulation given fast tract
  - 5.1.2.4 Novartis' s Fingolimod (FTY720)
  - 5.1.2.5 Sanofi-Aventis' s Teriflunomide set to file
  - 5.1.2.6 GW Sativex Investigational Cannabis-Based Treatment for MS
  - 5.1.2.7 Pfizer' s Lipitor (atorvastin) May See Extension through MS
5.2. Progressive forms of MS studies underway
- 5.2.1Biogen Idec and Genentech to deliver MS therapeutics through Monoclonal Antibodies (Mabs)
- 5.2.2 Bayhill Therapeutics Vacine (BHT-3009)
- 5.2.3 BHT-3009 Non-broad-based immunosuppressant mechanism
- 5.2.4 BioMS (MBP 8298) synthetic fragment Phase II study shows delayed progression of MS for 5 years
Table 5.2.MS phase III pipeline
Table 5.3. MS phase II pipeline
Table 5.4. MS phase I pipeline

Chapter 6. Children with MS

6.1 Paediatric MS
- 6.1.1Disease course of Paediatric MS
- 6.1.2Progression of Paediatric MS
- 6.1.3Challenges in diagnosis of paediatric MS
- 6.1.4Treatment options for Paediatric MS
Table 6.1 Paediatric MS Dosage of Disease Modifying Drugs

Chapter 7. Multiple Sclerosis Disease Modifying Drugs Market Analysis in the Seven Major Markets

7.1 US Market Analysis
- Chart 7.1 US Market Growth Rate 2002-2003
- Chart 7.2 US Health Budget Allocation in comparison to other Regions
- Chart 7.3. Population With and Without Health Insurance Coverage in the US
- Chart 7.4. Split of Health Insurance Providers in the US
- 7.1.2 US Expenditure on Pharmaceutical products
  - Chart 7.5.US Pharmaceutical Market Revenue 2005-2006
- 7.1.3 Overview of Approved MS Therapeutics in US Market
  - Chart 7.6. US one year cost to treat MS patients with the disease modifying drugs
- 7.1.4 US Major MS Therapeutics
  - 7.1.5.1 Biogen Idec' s Avonex
  - 7.1.5.2Biogen Idec Future targets for Avonex
  - 7.1.5.3Teva and Aventis (Sanofi-Aventis) Copaxane
  - 7.1.5.4 Merck Serono' s Rebif
  - 7.1.5.5 Bayer Schering Betaseron
  - 7.1.5.6 Biogen Idec and Elan' s Tysabri
  - 7.1.5.7 Antineoplastic Drugs (Relapse-Remitting & Secondary progressive)
  - 7.1.5.8Cancer Drug, Novantrone (Mixonatrone) Benefits MS Sufferers
  - 7.1.5.9 US MS Market Revenue Forecast 2007-2012
    - Table 7.1.US MS Disease Modifying Drugs Revenues ($bn), Forecast 2007-2012, 2017 & 2022
    - Chart 7.7.US MS Disease Modifying Drugs Revenues ($bn) Forecast 2007-2012, 2017 & 2022
      - Chart 7.8.1 US Avonex Combined Revenues ($m), 2003-2006
      - Chart 7.8.2 US Avonex Split Revenues ($m), 2003-2006
      - Chart 7.8.3 US Copaxone Combined Revenues ($m), 2003-2006
      - Chart 7.8.4 US Copaxone split Revenues ($m), 2003-2006
      - Chart 7.8.5 US Rebif Combined Revenues ($m), 2003-2006
      - Chart 7.8.6US Rebif split Revenues ($m), 2003-2006
      - Chart 7.8.7 US Befaseron Combined Revenues ($m), 2003-2006
      - Chart 7.8.8US Befaseron split Revenues ($m) 2003-2006
      - Chart 7.8.9 Tysabri split Revenues ($m), 2006
      - Chart 7.8.10US Novantrone combined Revenues ($m) 2003-2006
      - Chart 7.8.11 US Novantrone split Revenues ($m) 2003-2006
7.2. US MS Market Drivers and Restraints
- 7.2.1 Market Drivers
- 7.2.2 Market Restraints
7.2Japan Pharmaceutical Market Outlook
- Chart 7.12 Japan Pharmaceutical Revenues ($bn), 2004-2006
7.3 Japan' s Healthcare System
- 7.3.1 Medical Expenditure in Japan
  - Chart 7.13 Japan Medical Expenditure 1990s (JPY Trillions)
- 7.3.2 Japan Healthcare Strategic Reform
- 7.3.3 Strategic long-term care insurance care reforms
- 7.3.4 Japan Pharmaceutical Market Analysis
- 7.3.5 Overview of Approved MS Therapeutics in Japanese Market
  - 7.3.6.1 MS Product in the Japanese Market
    - Chart 7.14 Revenues of Three Major MS Drugs in Japan, 2006
  - 7.3.6.2 Biogen Idec' s Avonex Japanese Market Analysis
    - Chart 7.15 Avonex Split Revenues ($m) in Japan,2006
  - 7.3.6.3 Bayer Schering' s Betaseron Japanese Market Analysis
    - Chart 7.16 Betaferon Combined Revenues ($m) in Japan 2003-2006
    - Chart 7.17Betaferon Split Revenues ($m) in Japan 2003-2006
  - 7.3.6.4 Merck Serono' s Novantrone Japanese Market Analysis
    - Chart 7.18Novantrone Combined Revenues ($m) in Japan 2003-2006
    - Chart 7.19 Novantrone split Revenues ($m) in Japan 2003-2006
  - 7.3.6.5Japan MS Market Revenue Forecast 2007-2012,2017 & 2022
    - Table 7.2 Japan MS Major Drugs Revenue ($m) Forecast 2007-2012, 2017 & 2022
    - Chart 7.20 Japan MS Major Drugs Revenue ($m) Forecast 2007-2012
7.4 Market Drivers and Restraints
- 7.4.1 Market Drivers
- 7.4.2 Market Restraints
7.5 France Pharmaceutical Market Outlook
- Chart 7.21 France' s Pharmaceutical Market Revenues ($bn) 2002-2006
- 7.5.1 Healthcare System
- 7.5.2 France' s Health and Medical Expenditure
- 7.5.3 Major MS Product in the French Market
  - Chart 7.22 Major MS disease modifying drugs in France
  - 7.5.4.1 Biogen Idec' s Avonex Market Analysis in France
    - Chart 7.23 Biogen Idec combined Revenue ($m), 2003-2006
    - Chart 7.24 Biogen Idec Avonex Split Revenue ($m), 2003-2006
  - 7.5.4.2 Merck Serono' s Rebif Market Analysis in France
    - Chart 7.25 Rebif combined Revenue ($m), 2003-2006
    - Chart 7.26 Rebif Split Revenue ($m), 2003-2006
  - 7.5.4.3 Bayer Schering' s Betaferon Market Analysis in France
    - Chart 7.27 Betaferon combined Revenues ($m), 2003-2006
    - Chart 7.28 Betaferon Split Revenues ($m), 2003-2006
  - 7.5.4.4 Teva and Sanofi-Aventis' Copaxone Market Analysis in France
    - Chart 7.29 Copaxone combined Revenue ($m) 2003-2006
    - Chart 7.30 Copaxone split Revenue ($m) 2003-2006
  - 7.5.4.5 Merck Serono' s Novantrone Market Analysis in France
    - Chart 7.31 Serono' s declining Novantrone Revenue ($m), 2003-2006
7.6 Tysabri to reach the French Market
7.7 France' s MS Market Revenue ($m) Forecast 2007-2012, 2017 & 2022
- Chart 7.32 France Disease Modifying Drugs Revenue ($m) Forecast 2007-2012, 2017 & 2022
- Table 7.3 France Disease Modifying Drugs Revenues ($m), Forecast 2007-2012, 2017 & 2022
7.8 France' s MS Market Drivers and Restraints
- 7.8.1 Market Drivers
- 7.8.2 Market Restraints
7.9 Germany Pharmaceutical Outlook
- Chart 7.33 Germany' s Pharmaceutical Revenues ($bn), 2002-2007
- 7.9.1 Germany Healthcare System
- 7.9.2 Pharmaceutical Sector Reforms
- 7.9.3 Major MS Product in the German Market
  - Chart 7.34Major MS disease modifying drugs in Germany
  - 7.9.3.1 Merck Serono' s Rebif leading disease modifying drug in Germany 2006
    - Chart 7.35 Rebif' s Combined Revenues ($m), 2003-2006
    - Chart 7.36 Rebif' s Split Revenues ($m), 2003-2006
  - 7.9.3.2 Bayer Schering Betaferon German Market Analysis
    - Chart 7.37 Betaferon Combined Revenues ($m), 2003-2006
    - Chart 7.38 Betaferon Split Revenues ($m),.2003-2006
  - 7.9.3.3 Biogen Idec' s Avonex Market Analysis in Germany
    - Chart 7.39 Avonex Combined Revenues ($m), 2003-2006
    - Chart 7.40 Avonex Revenues ($m), 2003-2006
  - 7.9.3.4 Teva and Sanofi-Aventis Copaxone Market Analysis in Germany
    - Chart 7.41 Copaxone Combined Revenues ($m), 2003-2006
    - Chart 7.42 Copaxone Split Revenues ($m), 2003-2006
  - 7.9.3.5 Serono' s Novantrone Market Analysis in Germany
    - Chart 7.43 Novantrone Combined Revenues ($m), 2003-2006
  - 7.9.3.6 Biogen Idec and Elan' s Tysabri Market Analysis in Germany
    - Chart 7.41 Tysabri Split Revenues ($m), 2006
7.10 Germany MS Market Revenue ($m) Forecast 2007-2012, 2017 & 2022
- Table 7.4 Germany Disease Modifying Drugs Revenue ($m) Forecast 2007-2012, 2017 & 2022
- Chart 7.45 Germany Disease Modifying Drugs Revenue ($m) Forecast 2007-2012, 2017 & 2022
7.11 Germany MS Market Drivers and Restraints
- 7.11.1 Market Drivers
- 7.11.2 Market Restraints
7.12 UK Pharmaceutical Outlook
- Chart 7.46 UK Global Pharmaceutical Revenues ($bn), 2002-2006
- 7.12.1 UK Healthcare system
- 7.12.2 UK NHS and Department of Health
- 7.12.3 NHS and Private Healthcare
- 7.12.4 UK Healthcare Insurance Policies
- 7.12.5 Current NHS Prescription Volumes
- 7.12.6 Dominance of Generic Market
- 7.12.7 Major MS Product in the UK market
  - Chart 7.47 UK Major MS Disease Modifying Drugs
  - 7.12.7.1 Teva and Sanofi-Aventis' s Copaxone leading Disease modifying drug in the UK in 2006
    - Chart 7.48 Copaxone Combined Revenues ($m), 2003-2006
    - Chart 7.49 Copaxone Split Revenues ($m), 2003-2006
  - 7.12.7.2 Merck Serono' s Rebif UK market analysis
    - Chart 7.50 Rebif Combined Revenues ($m), 2003-2006
    - Chart 7.51 Rebif Split Revenues ($m), 2003-2006
  - 7.12.7.3 Biogen Idec Avonex UK market Growth
    - Chart 7.52 Avonex Combined Revenues ($m), 2003-2006
    - Chart 7.53 Avonex Split Revenues ($m), 2003-2006
  - 7.12.7.4 Bayer Schering Betaferon UK market Growth
    - Chart 7.54 Betaferon Combined Revenues ($m), 2003-2006
  - 7.12.7.5 Serono' s Novantrone UK Market
    - Chart 7.56 Novantrone Combined Revenues ($m), 2003-2006
7.13. NICE approves Biogen Idec and Elan' s Tysabri in the UK
7.14. UK Sector to grow and dominate MS Market in Europe
7.15.UK MS Market Revenues ($m) Forecast 2007-2012, 2017 & 2022
- Table 7.5 UK Disease Modifying Drugs Revenue ($m) Forecast 2007-2012, 2017 & 2022
- Chart 7.57 UK Disease Modifying Drugs Revenue ($m) Forecast 2007-2012, 2017 & 2022
7.16 UK MS Market Drivers and Restraints
- 7.16.1 Market Drivers
- 7.16.2 Market Restraints
7.17 Italy Pharmaceutical Outlook
- Chart 7.58 Italy' s Pharmaceutical Revenues ($bn), 2004-2006
- 7.17.1 Italy' s Healthcare System and Reforms
- 7.17.2 The Major MS Product in the Italian market
- Chart 7.59 Italy' s Major MS Disease Modifying Drugs
  - 7.17.2.1 Merck Serono' s Rebif leading beta interferon for MS in Italy
    - Chart 7.60 Rebif Combined Revenues ($m),2003-2006
    - Chart 7.61 Rebif Split Revenues ($m),2003-2006 Avonex Italy Market Analysis
  - 7.17.2.2 Biogen Idec' s Avonex Italy Market Analysis
    - Chart 7.62 Avonex Combined Revenues ($m),2003-2006
    - Chart 7.63 Avonex Split Revenues ($m),2003-2006
  - 7.17.2.3 Bayer Schering Betaseron Italy Market Analysis
    - Chart 7.64 Betaferon Total Revenues ($m),2003-2006
  - 7.17.2.4 Teva and Sanofi-Aventis' Copaxone Italy Market Analysis
    - Chart 7.65 Copaxone Combined Revenues ($m), 2003-2006
    - Chart 7.66 Copaxone Split Revenues ($m), 2003-2006
  - 7.17.2.5 Serono' s Novantrone Italy Market Analysis
    - Chart 7.67 Novantrone Total Revenues ($m), 2003-2006
7.18 Italy MS Market Revenue ($m) Forecast 2007-2012, 2017 & 2022
- Table 7.6 Italy Disease Modifying Drugs Revenue ($m) Forecast 2007-2012, 2017 & 2022
- Chart 7.68 Italy Disease Modifying Drugs Revenue ($m) Forecast 2007-2012, 2017 & 2022
7.19 Italy MS Market Drivers and Restraints
- 7.19.1 Market Drivers
- 7.19.2Market Restraints
7.20 Spain' s Pharmaceutical Outlook
- Chart 7.69 Spain Pharmaceutical Revenues ($bn), 2002-2006
- 7.20.1 The Major MS Product in the Spanish market
  - Chart 7.70 Major MS Disease Modifying Drugs in Spain
  - 7.20.1.1 Merck Serono' s Rebif leading MS product in Spain
    - Chart 7.71 Rebif Total Revenues ($m), 2003-2006
  - 7.19.2.2 Biogen Idec' s Avonex Spainish Market Analysis
    - Chart 7.72 Avonex Total Revenues ($m), 2003-2006
  - 7.20.1.3 Bayer Schering Betaferon Spain Market Analysis
    - Chart 7.73 Betaferon Total Revenues ($m), 2003-2006
  - 7.20.1.4Teva and Sanofi-Aventis Copaxone Spain Market Analysis
    - Chart 7.74 Copaxone Total Revenues ($m), 2003-2006
  - 7.20.1.5 Serono' s Novantone Spain Market analysis
    - Chart 7.75 Novantrone Total Revenues ($m), 2003-2006
7.21 Spain MS Market Revenues ($m) Forecast, 2007-2012, 2017 & 2022
- Table 7.7 Spain Disease Modifying Drugs Revenue ($m) Forecast 2007-2012, 2017 & 2022
- Chart 7.76 Spain Disease Modifying Drugs Revenue ($m) Forecast 2007-2012, 2017 & 2022
7.22 Spain MS Market Drivers and Restraints
- 7.22.1 Market Drivers
- 7.22.2 Market Restraints

Chapter 8. Conclusion

Table 8.1 Leading Companies with Oral MS Products late stage phase III studies to reach market by 2010

Organisations mentioned
Abbot Laboratories
Accentia Biopharma
Active Biotech
American Pharmaceutical Partners
Antisense Therapeutics
Artielle ImmunoTherapeutics
AstraZeneca
Bayer Schering
Bayhill Therapeutics
Bedford Labs
Berlex Laboratories
BioCryst
Biogen Idec
BioMS
Bristol Myers Squib
Caisse Nationale d' Assurance Maladie des Travailleurs Salariés (CNAMTS) C-Bio Cell Therapeutics ChemoCentryx Comite Economique des Sante (CEPS) Couverture Maladie Universelle (CMU) Dartmouth Dartmouth-Hitchcock Eisai Elan Corp Farmacija Gemacbio Genentech Genmab Genzyme GlaxoSmithKlien GW Pharmaceutical Hemispherx Biopharma
Hoffmann- La Roche
Hospices Civils de Lyon
Incyte
Janssen-Cilag
Japanese Ministry of Health and Welfare
LTKfarma
Mayne Pharma
Medarex
Medicinova
Merck Serono
Merrimack
Millennium Pharma
Mitsubishi Pharma Corporation
Mutualité Sociale Agricole (MSA)
Neuren
Neurology Research Group - Plymouth
Novartis
NovImmune
Nutra Pharma
Orchestra Therapeutics
Otsuka
Pepgen
Pfizer
Pipex
Protein Design Labs
ReceptoPharm
Régime Social des Indépendants (RSI)
Roche
S. Andrea Hospital
Sanofi-Aventis
Seattle Genetics
Sicor
Stanford and Pacific Pharmaceuticals
Stem Cell Therapeutics
Takeda Pharma
Tanabe
Teva
UCB
UK National Institute of Clinical Excellence (NICE)
University Medical Centre Groningen
University of Cambridge
University of Milano-Bicocca
University of San Fransico (UCSF)
University of Wisconsin
World Health Organisation (WHO)
Wyeth